Section snippets

Semaglutide for MASH

Semaglutide 2·4 mg once a week demonstrated significantly greater improvements in histology and fibrosis than did placebo in participants with metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, according to data from the phase 3 ESSENCE trial. Although the trial is ongoing, Phil Newsome (London, UK) presented data from the prespecified interim analysis at week 72 of the first 800 participants, of whom 534 had been randomly assigned to receive semaglutide and 266 had

Optimising steroid use in severe alcohol-associated hepatitis

Tapering the dose of corticosteroids is safer and just as efficacious as conventional fixed-dose corticosteroids for severe alcohol-associated hepatitis, according to results from the STASH trial, presented by Anand Kulkarni (Hyderabad, India). Patients with severe alcohol-associated hepatitis were randomly assigned to receive either a fixed-dose or tapering regimen. Patients in each group initially received 40 mg prednisolone a day for 7 days. Patients in the fixed dose group with a Lille

CM-101 in primary sclerosing cholangitis

CM-101, an anti-CCL24 monoclonal antibody, exhibited promising activity in patients with primary sclerosing cholangitis and had a safety profile similar to placebo, according to data from the phase 2 SPRING study. In this placebo-controlled trial, presented by Christopher Bowlus (Davis, CA, USA), patients with primary sclerosing cholangitis were randomly assigned to receive either CM-101 at 10 mg/kg (n=25), CM-101 at 20 mg/kg (n=31), or placebo (n=21) every 3 weeks for 15 weeks.

VK2809 for steatotic liver disease

The phase 2b VOYAGE trial examined the use of VK2809, a small molecule thyroid hormone receptor beta agonist prodrug that is selectively cleaved in hepatic tissue by cytochrome P450 3A4 to release a pharmacologically active metabolite, in individuals with biopsy-confirmed non-alcoholic fatty liver disease and fibrosis. Participants were randomly assigned to receive placebo or VK2809 at 1 mg/day, 2·5 mg/day, 5 mg/day, or 10 mg/day. Percentage change in MRI-PDFF at 3 months was –56·7% in the

中文翻译：

---

 2024 年肝脏会议

 部分片段

 用于 MASH 的索马鲁肽

根据 3 期 ESSENCE 试验的数据，与安慰剂相比，在患有代谢功能障碍相关脂肪性肝炎 （MASH） 伴 F2-F3 纤维化的参与者中，索马鲁肽 2·4 mg 每周一次在组织学和纤维化方面的改善显着更大。尽管试验正在进行中，但 Phil Newsome（英国伦敦）在前 800 名参与者的第 72 周展示了预先指定的中期分析数据，其中 534 名参与者被随机分配接受索马鲁肽治疗，266 名参与者

优化类固醇在重度酒精相关性肝炎中的使用

根据 Anand Kulkarni（印度海得拉巴）提出的 STASH 试验结果，逐渐减少皮质类固醇的剂量更安全，并且与传统固定剂量皮质类固醇治疗严重酒精相关性肝炎一样有效。患有严重酒精相关性肝炎的患者被随机分配接受固定剂量或逐渐减量方案。每组患者最初每天接受 40 mg 泼尼松龙，持续 7 天。固定剂量组 Lille

CM-101 治疗原发性硬化性胆管炎

根据 2 期 SPRING 研究的数据，CM-101 是一种抗 CCL24 单克隆抗体，在原发性硬化性胆管炎患者中表现出有希望的活性，并且具有与安慰剂相似的安全性。在这项由美国加利福尼亚州戴维斯市 Christopher Bowlus 提出的安慰剂对照试验中，原发性硬化性胆管炎患者被随机分配接受 10 mg/kg 的 CM-101 （n=25）、20 mg/kg 的 CM-101 （n=31） 或安慰剂 （n=21） 每 3 周一次，持续 15 周。

VK2809 治疗脂肪性肝病

2b 期 VOYAGE 试验检查了 VK2809 的使用，VK2809 是一种小分子甲状腺激素受体 β 激动剂前药，在肝组织中被细胞色素 P450 3A4 选择性裂解以释放药理活性代谢物，在活检证实的非酒精性脂肪性肝病和纤维化的个体中。参与者被随机分配接受安慰剂或 VK2809，剂量为 1 mg/天、2·5 mg/天、5 mg/天或 10 mg/天。3 个月时 MRI-PDFF 的百分比变化为 -56·7%